


# Comparative Clinical Effectiveness and Reimbursement

---

Gail R. Wilensky

Project HOPE

May 1, 2007



# What's the Problem?

---



- ◆ Spending growth rates are unsustainable
  - 2.5% annual growth faster than the economy (1960-2004)
- ◆ Lots of problems with patient safety
  - 95,000 medical errors
- ◆ Lots of problems with quality
  - On average, about half of what's appropriate

# Not *Just* a U.S. Issue

---



- ◆ U.S. spends a lot compared to other countries

*but...*

- ◆ *Growth rates* aren't *so* different

*although...*


- ◆ Canada, Germany, UK have done better in moderating spending

# To Change Current Patterns

---

Health Care needs ---

- ◆ Better information
- ◆ Better information systems
- ◆ Better incentives  
(or much more stringent controls)



# Current Disconnects in Healthcare; esp. in the U.S.

---




- ◆ Very sophisticated medical devices and procedures  
*but ---*
- ◆ “Cottage Industry” in terms of systems and information  
*and ---*
- ◆ No rewards for low cost, high-performing providers

# Comparative Effectiveness Information

## A Basic Building Block...

---



Information on...

“What works when, for whom, provided by...”

*also...*

Recognition that “technology” is rarely  
*always* effective or *never* effective



# Other Countries Are Ahead

---

- ◆ Have comparative effectiveness Centers
  - NICHE in United Kingdom
  - CDM in Canada
  - PBAC in Australia

*But, mostly* for Rx and devices

That misses where most of the money is!



# Other Countries...

---

- ◆ Mostly centralized process of CCE and economic assessments; literature review focus
- ◆ Agencies are usually part of government  
Not surprising – use centralized payer systems

*but...*

- ◆ *Differ* on mandatory nature of recommendations
- ◆ *Differ* on transparency of process



# U.S. Needs Something Different

---



“Center for Comparative Clinical Effectiveness”

- ◆ Elemental building block to “spending smarter”
- ◆ Focus on *conditions* rather than *interventions/therapeutics*; *procedures*, not just Rx and devices
- ◆ Invest in what is not yet known

*Dynamic Process...*

# Center Would Include Data from a Variety of Sources

---



- ◆ “Gold Standard” - - double-blinded RCT
- ◆ “Real World” RCT (Sean Tunis)
- ◆ Epidemiological studies
- ◆ Medical record analyses
- ◆ Administrative data

# To Be Useful Information *must be*

---

- ◆ Objective
- ◆ Credible
- ◆ Timely
- ◆ Transparent
- ◆ Understandable

# Different Views on Placing the Center

---


- ◆ In HHS?

Separate agency; FFRDC, AHRQ

- ◆ Free standing agency in Exec. Branch like FTC, FRB

- ◆ Quasi-Gov't IOM/NRC

“Close to Gov't...But not too close”



# Funding of Center

---



- ◆ *Preferred* Strategy:
  - direct appropriation
  - information is a “*Public Good*”
  
- ◆ *Realistic* Strategy:
  - direct appropriations
  - contribution from Medicare trust fund
  - Small “user fee” on all privately insured

# What the Center is *NOT*

---



- ◆ *Not* providing a new coverage requirement used for practice decisions/*reimbursement*
- ◆ *Not* a decision-making center
- ◆ *Not* a cost-effectiveness center

C/E and C/B important, but...  
should be dealt with separately

# Incentives Are Also a Big Problem

---



- ◆ Need to realign financial incentives
- ◆ Reward institutions/clinicians who provide high quality/efficiently produced care
- ◆ Also need to involve consumers  
“value-based” insurance;  
reward healthy lifestyles

# What This Means for Industry...

---



- ◆ Raises the bar for ↑ reimbursement  
“Get more if do more”
- ◆ Needn’t delay entry time to market - - especially if company “*goes at risk*” for addit’l reimbursement
- ◆ *Significant* change for the medical community will need support of “thought leaders”



# What Next?

---



- ◆ Lots of interest  
Industry, Insurance, Congress, MedPac, etc.
- ◆ Some legislation beginning to emerge

*But --*

Too soon to know

*And--*

“The devil is in the details”